Sign In
Buy LLY
$1,125.38
+42.15 (+3.89%)
At Close: Jun 04, 2026
Eli Lilly: Favorable Developments Continue Regarding Anti-Obesity Drug Franchise
03:22am, Monday, 13'th Nov 2023
Eli Lilly's anti-obesity drug Zepbound (tirzepatide) receives approval in the US and recommended approval in the EU. The SELECT study data shows that semaglutide 2.4 mg reduces major adverse cardiovas
Eli Lilly and Company (LLY) Presents at UBS Biopharma 2023 Conference (Transcript)
01:01pm, Saturday, 11'th Nov 2023
Eli Lilly and Company (NYSE:LLY ) UBS Biopharma 2023 Conference November 8, 2023 3:00 PM ET Company Participants Patrik Jonsson - President, Lilly Immunology Conference Call Participants Trung Huynh -
Cautious Investor? 2 Safe Stocks You Also Can Count on For Growth
05:00am, Saturday, 11'th Nov 2023
Eli Lilly just gained approval for a drug that could win big in the multibillion-dollar weight-loss market. Johnson & Johnson is focusing on its high-growth businesses after the recent spinoff of its
Eli Lilly's Tirzepatide approved in the EU days after US and UK approval
01:05pm, Friday, 10'th Nov 2023
Eli Lilly (LLY) stock price movement has experienced a whirlwind since Wednesday's approval of its diabetes medication, Tirzepatide, for chronic weight management in the United States and the United K
3 Stocks to Buy for Retirees Looking to Beat Inflation
12:20pm, Friday, 10'th Nov 2023
At 3.7%, inflation remains an issue. While consumer prices have come down from their peak of 9.1% in June 2022, the inflation rate in the U.S. remains well above the Federal Reserve's 2% annualized ta
Who's afraid of Ozempic? From restaurants to package makers, companies work to calm investors' GLP-1 jitters.
11:13am, Friday, 10'th Nov 2023
That's the message from many corporate executives who have lately been peppered with questions about how Wegovy, Ozempic and other drugs widely used for weight loss may impact their bottom line.
Where Will Eli Lilly Be in 5 Years?
10:23am, Friday, 10'th Nov 2023
Eli Lilly is pulling out all the stops to gain market share in a pair of key markets. It'll face stiff opposition from Novo Nordisk, among other contenders.
EU regulator backs Eli Lilly's Mounjaro for weight management
07:31am, Friday, 10'th Nov 2023
Europe's medicines regulator said on Friday its committee had recommended changing authorization terms for Eli Lilly's drug Mounjaro to include weight-management.
The Alzheimer's Drug Market Is Heating Up. Should You Buy the Leading Contenders' Stocks?
06:50am, Friday, 10'th Nov 2023
There's now more than one medicine on the market to treat Alzheimer's disease. Safety and efficacy will be the two major areas of future competition.
Will Eli Lilly's Zepbound be the next big weight-loss drug?
06:30am, Friday, 10'th Nov 2023
Eli Lilly & Co. NYSE: LLY reversed lower on November 9. This came after LLY stock advanced 3.20% after the company got regulators' OK for its weight-loss drug Zepbound.
British regulator confirms review of new pen for Lilly's Mounjaro drug
06:03am, Friday, 10'th Nov 2023
Britain's drug regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), on Friday confirmed that it is reviewing a new injection pen that Eli Lilly plans to use for the U.S. drugmake
Look Out, Ozempic and Wegovy: Eli Lilly Has a New Weight-Loss Drug in Town
05:49am, Friday, 10'th Nov 2023
Eli Lilly just won FDA approval for Zepbound (tirzepatide) as a chronic weight management treatment. Zepbound should generate huge sales over the coming years.
Eli Lilly Was Hoping for 5 Big Drug Launches This Year. Here's How It Has Done Thus Far.
05:40am, Friday, 10'th Nov 2023
Eli Lilly set some ambitious goals for 2023, highlighting a promising mix of assets in its portfolio. The company has obtained multiple drug approvals this year.
Eli Lilly CEO: We know there's high demand for weight-loss drugs and we're ready to meet it
05:17pm, Thursday, 09'th Nov 2023
David Ricks, Eli Lilly CEO, joins 'Closing Bell Overtime' to talk the FDA's approval of its new weight-loss drug, keeping up with demand for the drug, competition in the space and more.
Former FDA commissioner: Expect more competition in Eli Lilly and Novo Nordisk's weight-loss drugs
03:21pm, Thursday, 09'th Nov 2023
Former FDA commissioner Dr. Scott Gottlieb joins 'Power Lunch' to discuss Eli Lilly's highly anticipated weight-loss drug Zepbound, the demand and supply equation in the weight-loss drug space, and mo
